Surescript's EpiPen Citation 'Nothing New,' FTC Says
By Bryan Koenig · August 17, 2022, 5:30 PM EDT
The Federal Trade Commission assailed Surescripts for telling a D.C. federal judge that a Tenth Circuit decision sparing Mylan from antitrust allegations over the EpiPen bolsters Surescripts' bid to escape claims it uses exclusive...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login